首页 > 市场调查报告书 > 医疗设备

体外诊断生技设备

市场调查报告书

商品编码

1529027

化学发光免疫分析市场、副产品（仪器、消耗品、试剂[发光体、酵素标记]、软体和服务）、技术（CLEIA、ECLI）、样品类型、应用、最终用途 - 全球预测 2024 - 2032

Chemiluminescence Immunoassay Market, By Product (Instrument, Consumable, Reagent [Luminophore, Enzymatic Marker], Software & Service), Technology (CLEIA, ECLI), Sample Type, Application, End-use - Global Forecast 2024 - 2032

出版日期: 2024年05月14日 | 出版商:

Global Market Insights Inc. | 英文 278 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球化学发光免疫分析市场在 2024 年至 2032 年间的复合年增长率将达到 7.3%，主要得益于领先公司推出的产品数量不断增加。这些产品的特点通常是创新和增强的检测试剂盒，可提供卓越的灵敏度、特异性和更快的周转时间。诊断产业的主要参与者不断投资于研发，推出下一代 CLIA 系统，以满足临床实验室和研究机构不断变化的需求。

例如，2024 年 1 月，在印度医疗保健技术的突破性发展中，总部位于高知的 Agappe 公司推出了首款本土製造的 HX 系列血液学设备，以及人工智慧驱动的免疫学 CLIA 分析仪 Mispa i200。这标誌着诊断和患者护理新时代的开始。

这些新产品通常采用自动化和多重功能等先进技术，可简化实验室工作流程并提高效率。便携式和用户友好型 CLIA 设备的推出也扩大了市场范围，使小型实验室和护理点环境更容易进行这些测定。

化学发光免疫分析产业的总体规模根据产品、技术、样品类型、应用、最终用途和地区进行分类。

由于仪器的进步，化学发光免疫分析 (CLIA) 市场的需求不断增加。现代 CLIA 仪器具有更高的灵敏度、特异性和效率，使其成为临床诊断和研究不可或缺的一部分。这些仪器的特点是自动化和高通量能力，可简化实验室工作流程并提供快速、准确的结果。 CLIA仪器中多路復用和人工智慧等尖端技术的整合进一步拓宽了其应用范围，从检测传染病到监测慢性病。随着医疗保健提供者寻求可靠、高效的诊断工具，对复杂 CLIA 仪器的需求持续成长，推动市场扩张。

化学发光免疫分析（CLIA）市场受到电化学发光免疫分析（ECLIA）技术不断增长的需求的显着推动。 ECLIA 具有卓越的灵敏度、特异性和精确度，使其成为临床诊断和研究的首选。该技术能够提供快速、准确的结果，对于检测各种疾病（包括传染病和癌症）至关重要。 ECLIA 系统的自动化和高通量能力提高了实验室效率和工作流程。随着医疗保健行业越来越多地采用先进的诊断方法来改善患者的治疗效果，对 ECLIA 的需求持续增长，从而促进了 CLIA 市场的整体扩张。

在医疗保健基础设施的进步和对准确诊断解决方案的需求增加的推动下，亚太地区化学发光免疫分析 (CLIA) 市场正在经历显着增长。慢性病和传染病的盛行率不断上升，需要可靠、快速的检测方法，从而推动了 CLIA 技术的采用。政府措施和医疗保健支出的增加进一步推动了市场的发展，同时人们对先进诊断工具的认识和采用也不断提高。该地区不断扩大的医学研究和开发活动也促成了这一激增。因此，在这些医疗保健进步和不断增长的诊断需求的推动下，亚太地区 CLIA 市场有望大幅扩张。

产业生态系统分析
产业影响力
- 成长动力
  - 慢性病和传染病的盛行率不断上升
  - 化学发光免疫分析技术的进展
  - 扩大药物开发和临床研究的应用
- 产业陷阱与挑战
  - 严格的监管场景
  - 设备成本高
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
仪器仪表
- 自动化
- 半自动化
耗材
试剂
- 发光体标记
- 酵素标记物
软体与服务

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

主要趋势
化学发光酶技术（CLEIA）
电化学发光免疫分析 (ECLI)
微粒化学发光免疫分析

第 7 章：市场估计与预测：按样本类型，2021 - 2032

主要趋势
血
尿
唾液
其他样品类型

第 8 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
治疗药物监测
肿瘤学
心臟病学
内分泌科
传染病
自体免疫疾病
血液筛检
毒理学
新生儿筛检
代谢紊乱
胃肠病学
呼吸系统
其他应用

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

主要趋势
医院
临床实验室
製药和生物技术公司
其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Abbott Laboratories
Bio-Rad Laboratories, Inc.
Danaher corporation
DiaSorin S.p.A
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
H.U. Group Holdings, Inc.
Maccura Biotechnology Co., Ltd.
Revvity, Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Tosoh Corporation
Werfen

简介目录

Product Code: 9477

Global Chemiluminescence Immunoassay Market will witness a 7.3% CAGR between 2024 and 2032, driven significantly by the increasing number of product launches from leading companies. These launches are often characterized by innovative and enhanced assay kits that offer superior sensitivity, specificity, and faster turnaround times. Major players in the diagnostics industry are continuously investing in research and development to introduce next-generation CLIA systems that cater to the evolving needs of clinical laboratories and research institutions.

For instance, in January 2024, in a groundbreaking development for Indian healthcare technology, Agappe, a Kochi-based firm introduced its first indigenously manufactured HX series hematology equipment, along with the AI-powered Immunology CLIA analyzer, the Mispa i200. This marked the beginning of a new era in diagnostics and patient care.

These new products often incorporate advanced technologies, such as automation and multiplexing capabilities, which streamline laboratory workflows and improve efficiency. The introduction of portable and user-friendly CLIA devices has also expanded the market's reach, making these assays more accessible to smaller laboratories and point-of-care settings.

The overall Chemiluminescence Immunoassay Industry size is classified based on the product, technology, sample type, application, end-use, and region.

The chemiluminescence immunoassay (CLIA) market is experiencing increased demand driven by advancements in instruments. Modern CLIA instruments offer enhanced sensitivity, specificity, and efficiency, making them indispensable for clinical diagnostics and research. These instruments, characterized by their automation and high throughput capabilities, streamline laboratory workflows and provide rapid, accurate results. The integration of cutting-edge technologies, such as multiplexing and AI, in CLIA instruments has further broadened their application scope, from detecting infectious diseases to monitoring chronic conditions. As healthcare providers seek reliable and efficient diagnostic tools, the demand for sophisticated CLIA instruments continues to grow, propelling market expansion.

The chemiluminescence immunoassay (CLIA) market is significantly driven by the rising demand for electrochemiluminescence immunoassay (ECLIA) technologies. ECLIA offers superior sensitivity, specificity, and precision, making it a preferred choice in clinical diagnostics and research. This technology's ability to deliver rapid and accurate results is crucial for detecting various diseases, including infectious diseases and cancer. The automation and high throughput capabilities of ECLIA systems enhance laboratory efficiency and workflow. As the healthcare sector increasingly adopts advanced diagnostic methods for better patient outcomes, the demand for ECLIA continues to grow, contributing to the overall expansion of the CLIA market.

Asia Pacific chemiluminescence immunoassay (CLIA) market is experiencing significant growth, driven by advancements in healthcare infrastructure and increased demand for accurate diagnostic solutions. The rising prevalence of chronic and infectious diseases necessitates reliable and rapid testing methods, propelling the adoption of CLIA technology. Government initiatives and increased healthcare spending further boost the market, alongside growing awareness and adoption of advanced diagnostic tools. The region's expanding medical research and development activities also contribute to this surge. Consequently, the Asia Pacific CLIA market is poised for substantial expansion, driven by these healthcare advancements and increasing diagnostic needs.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic and infectious diseases
  - 3.2.1.2 Technological advancements in chemiluminescence immunoassay
  - 3.2.1.3 Expanding applications in drug development and clinical research
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of devices
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
- 5.2.1 Automated
- 5.2.2 Semi-automated
5.3 Consumables
5.4 Reagents
- 5.4.1 Luminophore markers
- 5.4.2 Enzymatic markers
5.5 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemiluminescence enzyme technology (CLEIA)
6.3 Electrochemiluminescence immunoassay (ECLI)
6.4 Microparticle chemiluminescence immunoassay

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Blood
7.3 Urine
7.4 Saliva
7.5 Other sample types

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Therapeutic drug monitoring
8.3 Oncology
8.4 Cardiology
8.5 Endocrinology
8.6 Infectious diseases
8.7 Autoimmune diseases
8.8 Blood screening
8.9 Toxicology
8.10 Newborn screening
8.11 Metabolic disorder
8.12 Gastroenterology
8.13 Respiratory
8.14 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Clinical laboratories
9.4 Pharmaceutical & biotechnology companies
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa